Nimodipine

Chemical formula: C₂₁H₂₆N₂O₇  Molecular mass: 418.44 g/mol  PubChem compound: 4497

Therapeutic indications

Nimodipine is indicated for:

Ischaemic neurological deficits following aneurysmal subarachnoid haemorrhage

Population group: only adults (18 years old or older)

Nimodipine is indicated for the treatment of ischaemic neurological deficits following aneurysmal subarachnoid haemorrhage.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Nimodipine is contraindicated in the following cases:

Myocardial infarction, unstable angina

at least one of
Myocardial infarction
Recent myocardial infarction
Preinfarction syndrome

Hypersensitivity to nimodipine

Nimodipine allergy

Rifampicin, phenobarbital, phenytoin, carbamazepine

at least one of
Rifampicin
Phenobarbital
Phenytoin
Carbamazepine

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: NIMOTOP 0.02% Solution for infusion
Summary of Product Characteristics (SPC) 2017: NIMOTOP Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈